Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance.
OBJECTIVE
To compare various computed tomography (CT) parameters to the positron emission tomography with computed tomography (PET-CT) response, with or without PET guidance for the response assessment of colorectal cancer (CRC) metastases treated by Y90 radioembolization.


METHODS
Thirty-six CRC metastases were retrospectively evaluated on 18F-Fluoro-Deoxy-Glucose PET-CT and contrast-enhanced computed tomography (CECT) performed at baseline and 2-3 months after Y90 radioembolization.


RESULTS
Median SUVmax values decreased from 11.39 to 6.71 after radioembolization (P<.001), and 23/36 (64%) metastases were categorized metabolic responses according to European Organisation for Research and Treatment of Cancer criteria. Only a decrease of the mean attenuation in the structural (P<.001) and metabolic active volume (P<.001) was observed. The change in these criteria was correlated with the change of SUVmax.
Department of Radiology, Section of Interventional Radiology and Division of Interventional Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago IL. Electronic address: mvouche@ulb.ac.be.
Michael
M
Vouche
Department of Radiology, Section of Interventional Radiology and Division of Interventional Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago IL; Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Northwestern University, Chicago, IL.
Riad
R
Salem
Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago IL.
Frank H
FH
Miller
Department of Radiology, Jules Bordet Institute, Brussels, Belgium.
Marc
M
Lemort
Department of Nuclear Medicine, Jules Bordet Institute, Brussels, Belgium.
Bruno
B
Vanderlinden
Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago IL.
Daniel
D
De Becker
Department of Digestive Oncology and Gastroenterology, Jules Bordet Institute, Brussels, Belgium.
Alain
A
Hendlisz
Department of Nuclear Medicine, Jules Bordet Institute, Brussels, Belgium.
Patrick
P
Flamen
D001918:Brachytherapy / Q000379:methods; D015179:Colorectal Neoplasms / Q000473:pathology*; D003287:Contrast Media; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D008099:Liver / Q000000981:diagnostic imaging; D008113:Liver Neoplasms / Q000175:diagnosis / Q000532:radiotherapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D003287:Contrast Media; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D019788:Fluorodeoxyglucose F18
Colorectal cancer; Liver metastases; PET-CT; Radioembolization; Yttrium-90